GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aarti Pharmalabs Ltd (NSE:AARTIPHARM) » Definitions » Debt-to-Asset

Aarti Pharmalabs (NSE:AARTIPHARM) Debt-to-Asset : 0.00 (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Aarti Pharmalabs Debt-to-Asset?

Aarti Pharmalabs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil. Aarti Pharmalabs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil. Aarti Pharmalabs's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was ₹0 Mil.


Aarti Pharmalabs Debt-to-Asset Historical Data

The historical data trend for Aarti Pharmalabs's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aarti Pharmalabs Debt-to-Asset Chart

Aarti Pharmalabs Annual Data
Trend Mar21 Mar22 Mar23 Mar24
Debt-to-Asset
0.07 0.17 0.10 0.11

Aarti Pharmalabs Quarterly Data
Mar21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.11 - 0.14 -

Competitive Comparison of Aarti Pharmalabs's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Aarti Pharmalabs's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aarti Pharmalabs's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aarti Pharmalabs's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Aarti Pharmalabs's Debt-to-Asset falls into.


;
;

Aarti Pharmalabs Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Aarti Pharmalabs's Debt-to-Asset for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(2685.561 + 166.979) / 25821.051
=0.11

Aarti Pharmalabs's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aarti Pharmalabs  (NSE:AARTIPHARM) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Aarti Pharmalabs Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Aarti Pharmalabs's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Aarti Pharmalabs Business Description

Traded in Other Exchanges
Address
Mulund Goregaon Link Road, 2nd floor, 204, Udyog Kshetra, Mulund West, Mumbai, MH, IND, 400080
Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. It manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, and xanthine derivatives in India. It also offers Contract Development and Manufacturing Services (CDMS) for drug substance (NCE, RSM, Intermediates) projects. Geographically, the company generates maximum revenue from its customers located outside India.

Aarti Pharmalabs Headlines

No Headlines